The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $499,151 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a novel diagnostic tool for early detection of syphilis infection. The key products/services to be delivered include: Functionalization of a recombinant, monoclonal antibody specific to Treponema pallidum peptidoglycan fragments, which are shed...
This federal Project Grant award, valued at $771,690.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate syphilis pathogenesis through genetic engineering of the syphilis-causing bacteria Treponema pallidum. The award aims to leverage new capabilities to genetically manipulate T. pallidum in order to better understand the role of antigenic variation in the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop and validate a rapid, point-of-care molecular test to detect Treponema pallidum antibiotic resistance. The key products to be delivered under this 2-year grant include: A multiplexed, point-of-care allele-specific loop-mediated isothermal amplification (AS-LAMP) assay to detect genetic markers of...
This federal Project Grant award of $466,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop rapid and ultrasensitive aptamer-based detection technologies for the diagnosis of Treponema pallidum infections, the causative agent of syphilis. The key products and services to be delivered through this funding include: 1) Developing aptamers that strongly and specifically bind to T....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is for the development of a direct diagnostic test for infectious and congenital syphilis. The $260,760 award to the University of Victoria aims to create a test that: (1) exhibits high sensitivity and specificity at all disease stages; (2) can differentiate active versus past infections; (3) can differentiate syphilis from yaws;...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid, integrated diagnostic assay for the detection of treponemal and nontreponemal antibodies associated with syphilis infection. The $698,349 award to The Pennsylvania State University will fund the creation of an electrochemical sensing platform that can simultaneously detect and semi-quantify these two...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $163,698 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Magic Lifescience, Inc. in Mountain View, CA to develop a novel point-of-care molecular diagnostic assay for syphilis as part of a multiplexed genital ulcer disease (GUD) test panel. The key objectives are to: 1) develop a PCR-based, multiplexed molecular assay for Treponema pallidum (syphilis) and other GUD pathogens using giant...
The University of Texas at Austin received a $212,357 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this project is to develop a rapid, sensitive, and specific point-of-care diagnostic test for detecting congenital syphilis in newborns, as well as an improved maternal syphilis diagnostic using vaginal self-swabs. The key products to be delivered include: A...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $264,750 to the University of Washington to optimize methods for recovering the Treponema pallidum genome from diverse clinical specimens. The project aims to develop a tiling amplicon sequencing approach to improve the analytical sensitivity and scale of T. pallidum genome recovery, which is challenging due to the...
The Virginia Commonwealth University was awarded a $746,009 Project Grant from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases. The grant falls under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research examining the cyclic-di-GMP signaling pathway and its role in the enzootic cycle of Lyme disease from November 18, 2022 through October 31, 2027. Specifically, the grant will fund...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $135,258 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) on September 13, 2024.
The grant will fund research to determine the biochemical features of Treponema pallidum peptidoglycan and the identity of released muropeptides, as well as elucidate the role of released peptidoglycan in the pathogenesis of syphilis. This research aims to increase the understanding of T. pallidum biology and syphilis pathology, and create a new CRISPR-based tool for the syphilis research field. The project will utilize liquid chromatography tandem mass spectrometry, HNOD2 reporter assays, and a rabbit model to achieve these objectives.